Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2008

01-12-2008 | Research Article

Adverse-drug-reaction related admissions to a hospital in Scotland

Authors: Yvonne Hopf, Margaret Watson, David Williams

Published in: International Journal of Clinical Pharmacy | Issue 6/2008

Login to get access

Abstract

Aims To apply established methods to identify ADR-related admissions and to determine the proportion which was preventable and which were caused by non-prescription medicines (NPMs). Methods This prospective, observational study screened all acute hospital admissions (n = 1,101) by ward pharmacists over a 2-week period. Suspected ADR-related admissions were reported to the researcher and established criteria were used to evaluate probability, causality and preventability of the ADR-related admissions. Results Of the 1,101 emergency admissions which occurred during the study period, 30 were categorised as ADR-related, equating to a prevalence of 2.7% (95% CI, 1.8–3.7%). Three (9.7%) of the 30 admissions were associated with NPMs. The ADR was the dominant reason for admission in 56.7% (n = 17/30) and only 13.3% (n = 4/30) of all reported admissions were assessed as unavoidable. Conclusion The proportion of ADR-related admissions was lower than in previous studies in the UK. A substantial proportion of ADRs was associated with NPMs, highlighting the need for greater awareness amongst patients, prescribers and other health care professionals regarding possible serious adverse effects caused by these medicines.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO. Safety of medicines – a guide to detecting and reporting adverse drug reactions. 2002. WHO. Safety of medicines – a guide to detecting and reporting adverse drug reactions. 2002.
2.
go back to reference Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Forthnightly review: adverse drug reactions. BMJ. 1998;316:1295–8.PubMed Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Forthnightly review: adverse drug reactions. BMJ. 1998;316:1295–8.PubMed
3.
go back to reference Muehlberger N, Schneeweiss S, Harford J. Adverse drug reaction monitoring – cost and benefit considerations. Part 1: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf. 1997;6(3):S71–7.PubMedCrossRef Muehlberger N, Schneeweiss S, Harford J. Adverse drug reaction monitoring – cost and benefit considerations. Part 1: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf. 1997;6(3):S71–7.PubMedCrossRef
7.
go back to reference Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5. doi:10.1136/qhc.12.4.280.PubMedCrossRef Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5. doi:10.​1136/​qhc.​12.​4.​280.PubMedCrossRef
11.
go back to reference Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. 1999;168:257–61.PubMed Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. 1999;168:257–61.PubMed
12.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMed Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMed
13.
go back to reference Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. In: Davies DM, Ferner RE, de Glanville H, editors. Davies’s textbook of adverse drug reactions. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1998. ISBN 0412824809. Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. In: Davies DM, Ferner RE, de Glanville H, editors. Davies’s textbook of adverse drug reactions. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1998. ISBN 0412824809.
14.
go back to reference Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection and the preventability of prevention. J Intern Med. 1990;228:83–90.PubMedCrossRef Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection and the preventability of prevention. J Intern Med. 1990;228:83–90.PubMedCrossRef
16.
go back to reference Bhalla N, Duggan C, Dhillon S. The incidence and nature of drug-related admissions to hospital. Pharm J. 2003;270:583–6. Bhalla N, Duggan C, Dhillon S. The incidence and nature of drug-related admissions to hospital. Pharm J. 2003;270:583–6.
19.
go back to reference Committee on Safety of Medicines. Annual report (2002), NHS Scotland Edinburgh. Committee on Safety of Medicines. Annual report (2002), NHS Scotland Edinburgh.
20.
go back to reference Teweleit S, Kuschel U, Hippius M, Goettler M, Bornschein B. Manifestation and possible prevention of adverse drug reactions (ADR) in pharmacotherapy of cardiovascular diseases. Med Klin. 2001;96(8):442–50. Manifestation and Praeventationsmoeglichkeiten unerwuenschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz-Kreislauf-Erkrankungen. doi:10.1007/PL00002226. Teweleit S, Kuschel U, Hippius M, Goettler M, Bornschein B. Manifestation and possible prevention of adverse drug reactions (ADR) in pharmacotherapy of cardiovascular diseases. Med Klin. 2001;96(8):442–50. Manifestation and Praeventationsmoeglichkeiten unerwuenschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz-Kreislauf-Erkrankungen. doi:10.​1007/​PL00002226.
Metadata
Title
Adverse-drug-reaction related admissions to a hospital in Scotland
Authors
Yvonne Hopf
Margaret Watson
David Williams
Publication date
01-12-2008
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2008
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9240-5

Other articles of this Issue 6/2008

International Journal of Clinical Pharmacy 6/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.